Our mission is to create equitable access to clinical trials for any patient, anywhere
Paradigm is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.
Learn more about Paradigm’s impact to reduce clinical trial burden and expand patient access to the best possible care.
Leadership
Kent Thoelke Chief Executive Officer
Jonathan Hirsch Chief Strategy & Growth Officer
Jay Trepanier Chief Financial Officer
Elijah Meerson Chief Technology Officer
Michelle Lee Chief Operating Officer
Board of Directors
Robert Nelsen Co-founder and Managing Director, ARCH Venture Partners
Hemant Taneja CEO and Managing Director, General Catalyst
Stephen Knight, MD President and Managing Partner, F-Prime
Kenneth C. Frazier Former Executive Chairman & CEO, Merck
General (Ret) Gustave F. Perna Former COO, Operation Warp Speed
Stephen Klasko, MD MBA Former CEO, Jefferson Health
Luciana Borio, MD Former Chief Scientist, U.S. Food & Drug Administration
Elena Viboch Partner, General Catalyst
Kent Thoelke Chief Executive Officer, Paradigm
Investors
Connect with Us
Stay up to date with the latest Paradigm news, updates and information.
